Vertex’s New Cystic Fibrosis Drug Treats the Cause, Not Just the Symptoms
Vertex Pharmaceutical shares soared 15% Wednesday as Wall Street cheered the results of a late-stage study of its new cystic fibrosis drug, an experimental treatment that targets the underlying cause of the disease rather than …